Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of action of glatiramer acetate in multiple sclerosis

27 Mar 2001

Abstract excerpt

Glatiramer acetate (GA, Copaxone [Teva Pharmaceuticals, Kansas City, MO], formerly known as copolymer-1) and interferon- (IFN)-β are both used for the immunomodulatory treatment of multiple sclerosis, but they act in different ways. Four major mechanisms of GA have been identified: 1) competition with myelin-basic protein (MBP) for binding to major histocompatibility complex (MHC) molecules; 2) competition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Immunotherapy and Immune Responses
Share to Multiple Sclerosis Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11288751
DOI: 10.1212/wnl.56.6.702

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Mechanisms of action of glatiramer acetate in multiple sclerosisPMID 11288751Read ↗

Gene expression analysis reveals functional pathways of glatiramer acetate activationSemantic proximity Read ↗

Pathogenic mechanisms and experimental models of multiple sclerosis.Semantic proximity Read ↗

Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein.Semantic proximity Read ↗

Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.Semantic proximity Read ↗

Immunopharmacological consequences of immune responses to therapeutic interferon betaSemantic proximity Read ↗

Safety and Immune Effects of Blocking CD40 Ligand in Multiple SclerosisSemantic proximity Read ↗

HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosisSemantic proximity Read ↗

Current trends in multiple sclerosis research: an update on pathogenic concepts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.